Graduated compression stocking and intermittent pneumatic compression device length selection

Superior hemodynamic performance of a thigh-length versus knee-length intermittent pneumatic compression device

OBJECTIVE

There is a lack of consensus regarding which length of intermittent pneumatic compression (IPC) device provides optimal thromboprophylaxis. This trial was conducted to compare hemodynamic performance of a thigh-length and knee-length IPC device. The hypothesis is that thigh-length IPC will be more efficient in preventing stasis.

METHODS

This single-center trial tested the thigh-length sleeve (TLS) and knee-length sleeve (KLS) in 47 healthy volunteers. Peak systolic velocity and total volume flow were measured at rest and during the 11-second compression cycle. Measurements were obtained at the popliteal vein for the KLS and at the common femoral vein for the TLS.

RESULTS

The study was completed by 47 volunteers (32 women, 15 men), who were a mean age of 39.7 years (range, 18-68 years). There was a statistically significant difference in augmented total volume flow and peak systolic velocity between the KLS and TLS favoring the TLS: median total volume flow was 357.54 mL/min for the KLS vs 668.21 mL/min for the TLS (P < .0001), and median peak systolic velocity was 47.70 cm/s for the KLS vs 58.47 cm/s for the TLS (P = .0019).

CONCLUSIONS

This trial suggests that the improved hemodynamic effects of a thigh-length IPC system may provide superior thromboprophylaxis to a knee-length IPC.

Improving venous thromboembolism prevention processes and outcomes at a community hospital

BACKGROUND

Venous thromboembolism (VTE) is a cause of significant morbidity and mortality in hospitalized patients in the United States. Quality improvement (QI) strategies to increase the rates of prophylaxis in patients at-risk for VTE have been shown to be successful. The development of a formal, active strategy addressing the prevention of VTE, as a written, institutionwide VTE prophylaxis policy, presents a challenge for hospitals

METHODS

In 2007 a multidisciplinary VTE committee was initiated to develop and implement a hospitalwide QI program to standardize VTE risk assessment and prophylaxis prescribing practices at Saint Francis Hospital (Tulsa, Oklahoma). The QI program included clinician education, VTE order set and electronic trigger implementation, and changes in mechanical prophylaxis usage.

RESULTS

The VTE prophylaxis order set was successfully piloted and implemented hospitalwide within three months of the project's initiation. Standardization of VTE prophylaxis practices across surgical and medical specialties was the key aim of this QI program. As a result, patient-related outcomes were also improved. The number of hospital-acquired VTE events decreased from 123 (0.39%) in 2008 to 99 (0.32%) in 2009 and 87 (0.27%) in 2010, and a reduction in the VTE rate between 2008 and 2010 of 31.6%. There was a significant decrease between 2008 and 2010 in the number of hospital-acquired VTE events (p = .035).

CONCLUSIONS

Keys to the success of this QI program included leveraging multidisciplinary VTE committee members, physician champions, multiple approaches to communication and education, and providing evidence to support the changes. Sharing the hospital's QI process may provide a model for other hospitals challenged with developing and sustaining positive outcomes in patients at risk for VTE.

Deep vein thrombosis: a clinical review

Background:

Deep vein thrombosis (DVT) is the formation of blood clots (thrombi) in the deep veins. It commonly affects the deep leg veins (such as the calf veins, femoral vein, or popliteal vein) or the deep veins of the pelvis. It is a potentially dangerous condition that can lead to preventable morbidity and mortality.

Aim:

To present an update on the causes and management of DVT.

Methods:

A review of publications obtained from Medline search, medical libraries, and Google.

Results:

DVT affects 0.1% of persons per year. It is predominantly a disease of the elderly and has a slight male preponderance. The approach to making a diagnosis currently involves an algorithm combining pretest probability, D-dimer testing, and compression ultrasonography. This will guide further investigations if necessary. Prophylaxis is both mechanical and pharmacological. The goals of treatment are to prevent extension of thrombi, pulmonary embolism, recurrence of thrombi, and the development of complications such as pulmonary hypertension and post-thrombotic syndrome.

Conclusion:

DVT is a potentially dangerous condition with a myriad of risk factors. Prophylaxis is very important and can be mechanical and pharmacological. The mainstay of treatment is anticoagulant therapy. Low-molecular-weight heparin, unfractionated heparin, and vitamin K antagonists have been the treatment of choice. Currently anticoagulants specifically targeting components of the common pathway have been recommended for prophylaxis. These include fondaparinux, a selective indirect factor Xa inhibitor and the new oral selective direct thrombin inhibitors (dabigatran) and selective factor Xa inhibitors (rivaroxaban and apixaban). Others are currently undergoing trials. Thrombolytics and vena caval filters are very rarely indicated in special circumstances.